Investor Presentaiton

21 * Innovative R&D - In-house R&D Enhance in-house R&D capabilities Henlius 2 Henlius Pipeline covers oncology, autoimmune areas etc.; launched China's first biosimilar product Han Li Kang, and the first mAb product Han Qu You approved in both China and EU Fochon FOCHON PHARMACEUTICALS Pipeline candidates FCN-437 in Phase 3 clinical trial; FCN-159 (MEK1/2) clinical trial in China, U.S. and Europe; the right outside of Chinese Mainland, Hong Kong and Macau of FCN-338 (BCL-2) was granted to Lilly ①⑦ 复星弘创 Novelstar Novelstar FOSUN ORINOVE Fosun Orinnove First-in-Class R&D strategy. Pipeline candidate Orin1001 is with novel target, MOA and compound A FOSUN PHARMA Company R&D of special formulation for multiple DDSS including transdermal, inhalation, slow- release and controlled-release DOU Gene Therapy Platform siRNA Therapy Platform Figure number: GS(2016)1666 XXX Nanobody and Bispecific Antibody Platform Oncolytic Virus Platform Personalized Therapeutic Tumor Vaccine (AC-NP) & Multi-specific Immuno-nano Therapy (MINP) mRNA Platform Cell Therapy Platform Fusion Protein Platform

View entire presentation